Literature DB >> 8854049

Molecular basis and clinical application of biological markers of bone turnover.

M S Calvo1, D R Eyre, C M Gundberg.   

Abstract

An ideal battery of tests would include indices of bone resorption and formation. They should be unique to bone, reflect total skeletal activity, and should correlate with traditional measures of bone remodeling activity, such as radiocalcium kinetics, histomorphometry, or changes in bone mass. Factors that confound their measurement, such as circadian rhythms, diet, age, sex, bone mass, liver function, and kidney clearance rates, should be clearly defined (Fig. 9). To date, no bone marker has been established to meet all these criteria, and each marker may have its own specific advantages and limitations. There are still questions that must be answered before there can be complete confidence in the information gained from measurement of any of the bone markers. Furthermore, it should be emphasized that none of the markers are diagnostic for any particular bone disease and cannot be used for this purpose in individual patients. Nevertheless, recent advances in research and development have provided assays with increased specificity, sensitivity, and availability. Because of this, bone markers can be used for a variety of important purposes: as tools for basic bone biology research, for defining general physiological phenomenon in clinical studies or drug trials, and for following individual patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8854049     DOI: 10.1210/edrv-17-4-333

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  70 in total

Review 1.  Bone loss and glucocorticoid therapy in patients with respiratory disease.

Authors:  A Fairney
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 3.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

4.  Quantitative trait locus on chromosome X affects bone loss after maturation in mice.

Authors:  Shuzo Okudaira; Motoyuki Shimizu; Bungo Otsuki; Rika Nakanishi; Akira Ohta; Keiichi Higuchi; Masanori Hosokawa; Tadao Tsuboyama; Takashi Nakamura
Journal:  J Bone Miner Metab       Date:  2010-03-31       Impact factor: 2.626

Review 5.  Is there a role for exercise in the prevention of osteoporotic fractures?

Authors:  O M Rutherford
Journal:  Br J Sports Med       Date:  1999-12       Impact factor: 13.800

Review 6.  A four-season molecule: osteocalcin. Updates in its physiological roles.

Authors:  Giovanni Lombardi; Silvia Perego; Livio Luzi; Giuseppe Banfi
Journal:  Endocrine       Date:  2014-08-27       Impact factor: 3.633

Review 7.  Diagnostic biomarkers for oral and periodontal diseases.

Authors:  Mario Taba; Janet Kinney; Amy S Kim; William V Giannobile
Journal:  Dent Clin North Am       Date:  2005-07

8.  Suppressed bone remodeling in black bears conserves energy and bone mass during hibernation.

Authors:  Meghan McGee-Lawrence; Patricia Buckendahl; Caren Carpenter; Kim Henriksen; Michael Vaughan; Seth Donahue
Journal:  J Exp Biol       Date:  2015-07       Impact factor: 3.312

9.  Macrophage-elicited osteoclastogenesis in response to bacterial stimulation requires Toll-like receptor 2-dependent tumor necrosis factor-alpha production.

Authors:  Takashi Ukai; Hiromichi Yumoto; Frank C Gibson; Caroline Attardo Genco
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

10.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.